Recent discussions on X about Ardelyx (ARDX) have been buzzing with activity, particularly around insider trading and upcoming legal developments. Posts on the platform highlight a significant insider sale by a top executive, sparking debates about the implications for the company's future. Many users are also focused on a pending CMS case, with some speculating that a favorable outcome could drive the stock price significantly higher.
Additionally, there’s notable chatter about Ardelyx’s product performance, with some users pointing to record-breaking script numbers as a sign of strong growth potential. Others are sharing technical chart insights and predictions for the stock’s movement in the coming months. The conversation reflects a mix of optimism and caution as investors weigh these recent developments.
Note: This discussion summary was generated from an AI condensation of post data.
Ardelyx Insider Trading Activity
Ardelyx insiders have traded $ARDX stock on the open market 21 times in the past 6 months. Of those trades, 4 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- DAVID M MOTT has made 4 purchases buying 881,377 shares for an estimated $3,403,196 and 0 sales.
- MICHAEL RAAB (President & CEO) has made 0 purchases and 5 sales selling 217,504 shares for an estimated $1,053,598.
- LAURA A WILLIAMS (Chief Patient Officer) has made 0 purchases and 4 sales selling 92,682 shares for an estimated $553,025.
- ERIC DUANE FOSTER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 17,815 shares for an estimated $101,034.
- MIKE KELLIHER (Chief Business Officer) has made 0 purchases and 2 sales selling 19,939 shares for an estimated $91,402.
- JUSTIN A RENZ (Chief Financial Officer) has made 0 purchases and 2 sales selling 14,255 shares for an estimated $71,200.
- ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 11,833 shares for an estimated $59,102.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Ardelyx Hedge Fund Activity
We have seen 107 institutional investors add shares of Ardelyx stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 9,919,066 shares (-39.7%) from their portfolio in Q2 2025, for an estimated $38,882,738
- EVENTIDE ASSET MANAGEMENT, LLC removed 5,600,764 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $27,499,751
- MILLENNIUM MANAGEMENT LLC added 5,197,967 shares (+80.4%) to their portfolio in Q2 2025, for an estimated $20,376,030
- MARSHALL WACE, LLP added 2,866,843 shares (+34.2%) to their portfolio in Q2 2025, for an estimated $11,238,024
- BLACKROCK, INC. added 2,799,200 shares (+15.6%) to their portfolio in Q2 2025, for an estimated $10,972,864
- BANK OF AMERICA CORP /DE/ added 2,600,080 shares (+88.8%) to their portfolio in Q2 2025, for an estimated $10,192,313
- JONES FINANCIAL COMPANIES LLLP added 1,832,320 shares (+16861.3%) to their portfolio in Q2 2025, for an estimated $7,182,694
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Ardelyx Government Contracts
We have seen $34,284 of award payments to $ARDX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- XPHOZAH: $34,284
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Ardelyx Analyst Ratings
Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/18/2025
- Citigroup issued a "Buy" rating on 05/02/2025
- Ladenburg Thalmann issued a "Buy" rating on 03/07/2025
- Scotiabank issued a "Sector Outperform" rating on 03/07/2025
To track analyst ratings and price targets for Ardelyx, check out Quiver Quantitative's $ARDX forecast page.
Ardelyx Price Targets
Multiple analysts have issued price targets for $ARDX recently. We have seen 7 analysts offer price targets for $ARDX in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Christopher Raymond from Piper Sandler set a target price of $9.0 on 08/06/2025
- Laura Chico from Wedbush set a target price of $14.0 on 08/05/2025
- Ryan Deschner from Raymond James set a target price of $12.0 on 08/05/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $10.0 on 06/18/2025
- Yigal Nochomovitz from Citigroup set a target price of $10.0 on 05/02/2025
- Louise Chen from Scotiabank set a target price of $15.0 on 03/07/2025
- Aydin Huseynov from Ladenburg Thalmann set a target price of $11.0 on 03/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
